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BACKGROUND
Ultrasound-guided foam sclerotherapy and endovenous laser ablation are widely used 
alternatives to surgery for the treatment of varicose veins, but their comparative 
effectiveness and safety remain uncertain.
METHODS
In a randomized trial involving 798 participants with primary varicose veins at 11 
centers in the United Kingdom, we compared the outcomes of foam, laser, and surgi-
cal treatments. Primary outcomes at 6 months were disease-specific quality of life 
and generic quality of life, as measured on several scales. Secondary outcomes 
included complications and measures of clinical success.
RESULTS
After adjustment for baseline scores and other covariates, the mean disease-spe-
cific quality of life was slightly worse after treatment with foam than after surgery 
(P = 0.006) but was similar in the laser and surgery groups. There were no signifi-
cant differences between the surgery group and the foam or the laser group in 
measures of generic quality of life. The frequency of procedural complications was 
similar in the foam group (6%) and the surgery group (7%) but was lower in the 
laser group (1%) than in the surgery group (P<0.001); the frequency of serious ad-
verse events (approximately 3%) was similar among the groups. Measures of clinical 
success were similar among the groups, but successful ablation of the main trunks 
of the saphenous vein was less common in the foam group than in the surgery 
group (P<0.001).
CONCLUSIONS
Quality-of-life measures were generally similar among the study groups, with the 
exception of a slightly worse disease-specific quality of life in the foam group than 
in the surgery group. All treatments had similar clinical efficacy, but complica-
tions were less frequent after laser treatment and ablation rates were lower after 
foam treatment. (Funded by the Health Technology Assessment Programme of 
the National Institute for Health Research; Current Controlled Trials number, 
ISRCTN51995477.)
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U
ltrasound-guided foam sclero-
therapy and thermal ablation techniques 
such as endovenous laser ablation have 
become widely used alternatives to surgery for the 
treatment of varicose veins. Previous randomized 
trials and meta-analyses have shown these treat-
ments to be effective in terms of short-term tech-
nical success and clinician-reported outcomes.1-19 
Clinical practice guidelines recommend the use of 
patient-reported quality of life to assess the out-
comes of treatment of varicose veins.20 Quality of 
life was a primary outcome measure in two small 
randomized trials that compared surgery and en-
dovenous laser ablation,5,9 but to our knowledge, 
it has not been assessed as a primary outcome in 
randomized trials involving foam sclerotherapy.
We performed the Comparison of Laser, Sur-
gery, and Foam Sclerotherapy (CLASS) trial, a large, 
multicenter, randomized, comparative-effective-
ness trial, to assess quality of life and other out-
comes of treatment of varicose veins. We com-
pared foam sclerotherapy, laser therapy (with 
subsequent foam sclerotherapy for residual vari-
cosities, if required), and surgery.21
Me thods
Patients
We recruited patients requiring treatment of vari-
cose veins in 11 vascular surgery departments in 
the United Kingdom between November 2008 and 
October 2012. All patients were assessed by a vas-
cular surgeon and underwent initial duplex ultra-
sonographic scanning to assess suitability for 
treatment and entry into the study. Inclusion crite-
ria were an age of 18 years or older, the presence 
of unilateral or bilateral primary symptomatic 
varicose veins (grade C
2
 or higher according to the 
clinical, etiologic, anatomical, and pathophysio-
logical [CEAP] classification system, with C
0
 indi-
cating no signs of venous disease, C
1
 telangiecta-
ses or veins ≤3 mm in diameter, C
2
 varicose veins 
>3 mm in diameter, C
3
 the presence of edema, C
4
 
skin and subcutaneous changes, C
5
 healed ulcers, 
and C
6
 active ulceration,22), and reflux of the great 
or small saphenous veins of more than 1 second 
on duplex ultrasonography. Exclusion criteria were 
current deep-vein thrombosis, acute superficial-
vein thrombosis, a diameter of the main truncal 
saphenous vein of less than 3 mm or more than 
15 mm, tortuous veins considered to be unsuitable 
for laser treatment, and contraindications to the 
use of foam or to general or regional anesthesia.
Randomization and Study Treatment
A computer-generated randomization system was 
used and was managed by the Centre for Health-
care Randomised Trials, University of Aberdeen, 
Aberdeen, United Kingdom. Participants under-
went randomization with even assignments to all 
treatment options available at each investigating 
center and with stratification according to the 
number of available options (stratum A, eight 
hospitals offering all three treatment options; and 
stratum B, three hospitals offering treatment with 
only foam or surgery). Treatments were assigned 
with the use of a minimization algorithm that 
included center, age (<50 years or ≥50 years), sex, 
reflux of either the great or the small saphenous 
veins (or both), and the presence or absence of 
unilateral or bilateral varicose veins.
Details of treatment methods are described in 
the published protocol21 (available with the full 
text of this article at NEJM.org). Briefly, surgery 
consisted of proximal ligation and stripping (of 
the great saphenous vein only) and concurrent 
phlebectomies. Foam was produced with the use 
of the Tessari technique21 at a ratio of 0.5 ml of 
sodium tetradecyl sulfate to 1.5 ml of air (3% so-
dium tetradecyl sulfate for saphenous veins and 
1% for varicosities, with a maximum of 12 ml of 
foam per session). The use of sodium tetradecyl 
sulfate is licensed, but the trial involved its off-
license use as a foam rather than as its manu-
factured liquid form. Laser ablation of truncal 
saphenous veins performed while the patient was 
under local anesthesia was followed by foam 
sclerotherapy to residual varicosities at the 6-week 
follow-up if required, with the exception that one 
center performed concurrent phlebectomies.
Outcome Measures
Outcomes were assessed at baseline and at 6 weeks 
and 6 months after treatment. The primary out-
come measures were patient-reported disease-
specific quality of life, measured with the use of 
the Aberdeen Varicose Veins Questionnaire (AVVQ), 
and patient-reported generic (i.e., general) qual-
ity of life, measured at 6 months after treatment 
with the use of the EuroQoL Group 5-Dimension 
Self-Report Questionnaire (EQ-5D) and the Med-
ical Outcomes Study 36-Item Short-Form Health 
Survey (SF-36). Another prespecified primary out-
come for this trial — 5-year estimated cost-effec-
tiveness, measured as cost per quality-adjusted 
life-year gained — is not reported here.
The AVVQ is an internationally validated 
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change-responsive tool for the assessment of qual-
ity of life in patients with varicose veins.20,23-26 It 
consists of 12 questions and a set of mannequin 
legs on which participants are asked to draw their 
veins. Scores range from 0 to 100, with higher 
scores indicating a worse quality of life. The EQ-5D 
is a standardized index valuation for health sta-
tus; it includes five dimensions (mobility, self-care, 
usual activities, pain or discomfort, and anxiety 
or depression; scores range from −0.594 to 1.000, 
with higher scores indicating a better quality of 
life) and a visual analogue scale (EQ-5D VAS; 
scores range from 0 to 100, with higher scores 
indicating better health).27 The SF-36 is a vali-
dated and reliable assessment of quality of life 
and is widely used for a variety of clinical condi-
tions.28 The 36 questions assess eight domains and 
yield two summary scores (the physical compo-
nent and the mental component), with each sum-
mary score ranging from 0 to 100 and higher 
scores indicating greater well-being. For all these 
measures of quality of life, minimal clinically im-
portant differences after treatment for varicose 
veins are not known.
Secondary outcomes were as follows: clinical 
success at 6 weeks and 6 months, as measured 
by the proportion of patients with residual vari-
cose veins (assessed by the participant and the 
nurse), venous clinical severity score (a score com-
posed of nine categories relating to symptoms or 
signs of venous disease and one category relat-
ing to the use of compression; scores range from 
0 [no venous disease] to 30 [most severe venous 
disease]), and complications (assessed by the sur-
geon or nurse); quality of life according to the 
AVVQ, EQ-5D, and SF-36 at 6 weeks; the EQ-5D 
VAS and the eight SF-36 domains at 6 weeks and 
6 months; and ablation rates of the main trunks 
of the saphenous vein according to duplex ultra-
sonography at 6 weeks and 6 months, assessed 
with the use of a standardized technique22 and 
reporting tool by independent, accredited vascu-
lar technologists (with the exception of one cen-
ter where scanning was performed by a surgeon 
who had not performed the treatment). Blinding 
with respect to the treatment used was not fea-
sible.
Study Oversight
The trial was approved by the research ethics com-
mittee and the Medicines and Healthcare Prod-
ucts Regulatory Authority. Written informed con-
sent was obtained from all participants. The trial 
was overseen by a trial steering committee and 
an independent data and safety monitoring com-
mittee. Data analysis was performed by statisti-
cians at the Centre for Healthcare Randomised 
Trials. The project management group (the first six 
and the last four authors) takes responsibility for 
the accuracy and completeness of the data, analy-
ses, and reporting and for the fidelity of the study 
to the protocol.
Statistical Analysis
An intention-to-treat analysis was performed for 
the prespecified comparisons of treatment with 
foam versus surgery, involving participants from 
strata A and B, and treatment with laser versus 
surgery, involving participants from stratum A. 
In addition, we performed a post hoc analysis of 
laser therapy versus foam sclerotherapy, involv-
ing participants from stratum A. The principal 
analysis of the trial was performed when all par-
ticipants had completed the 6-month follow-up. 
Study analyses were conducted according to a 
prespecified statistical plan (available with the 
protocol at NEJM.org) with the use of SAS soft-
ware, version 9.3 (SAS Institute).
To analyze comparisons between groups, we 
used general linear models with adjustments for 
covariates used in the minimization algorithm 
and, where possible, adjustments for baseline 
scores (AVVQ, EQ-5D, SF-36, and venous clinical 
severity scores). No adjustment was prespecified 
for multiple comparisons. However, for the sec-
ondary outcome measures presented here, we 
consider differences to be significant only for 
P values of less than 0.005. We analyzed the con-
tinuous outcomes with mixed-model repeated-
measures analysis, with a compound-symmetry 
covariance matrix and with center fitted as a ran-
dom effect. Saphenous-vein ablation rates were 
analyzed with the use of ordinal logistic regres-
sion, and rates of complications were analyzed 
with the use of binary logistic regression. Sensi-
tivity analyses (see Table S1 in the Supplemen-
tary Appendix, available at NEJM.org) were car-
ried out in the case of missing AVVQ responses 
at 6 months.29
The initial planned sample size was 1015 pa-
tients, which, at a two-sided 5% significance level, 
would provide more than 90% power to detect a 
difference of 0.25 SD in the AVVQ score for the 
comparison of foam sclerotherapy with surgery,30,31 
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and 80% power to detect a difference of 0.25 SD 
in the AVVQ score for the comparison of laser 
with surgery. The data and safety monitoring com-
mittee and trial steering committee approved a 
revised recruitment target of 779 patients on the 
basis of data showing that the correlation between 
the AVVQ score at baseline and at 6 months was 
better than originally assumed. Only the data and 
safety monitoring committee was aware of the 
outcome data according to group assignment dur-
ing the trial.
R esult s
Patients and Treatment
Of 6592 participants referred from primary care 
for consideration of treatment, 3369 (51.1%) met 
the eligibility criteria, of whom 798 (23.7%) con-
sented to participation in the trial (Fig. 1) and 
785 were included in the trial. The reasons for 
ineligibility and the reasons that eligible patients 
declined randomization are summarized in Ta-
ble S2 in the Supplementary Appendix. Most in-
eligible participants did not require treatment of 
the truncal saphenous veins (i.e., the patients were 
asymptomatic or did not have reflux) or had re-
current varicose veins. Most of the eligible par-
ticipants who declined to undergo randomization 
had a preference for a specific treatment. Baseline 
demographic and clinical data for the three groups 
are shown in Table 1. Baseline characteristics were 
generally similar among the groups, with the fol-
lowing exceptions: the diameter of the great sa-
phenous vein was larger in the laser group than 
in the foam group (P = 0.008), the incidence of 
reflux below the knee was greater in the foam 
group than in the laser group (P = 0.03), and the 
incidence of deep venous reflux was less in the 
surgery group than in the foam group (P = 0.006). 
The proportion of treated participants who re-
ceived their assigned treatment was 97% in the 
laser group, 93% in the foam group, and 87% in 
the surgery group. Fully trained staff surgeons 
performed 73% of the laser procedures, 77% of 
the foam procedures, and 59% of the surgical 
procedures; the remaining procedures were per-
formed by surgical trainees. A mean of 83 J per 
square centimeter was achieved per laser pulse. 
Participants who were randomly assigned to treat-
ment with foam or laser had the option of treat-
ment with foam for any residual varicosities at the 
6-week follow-up assessment; such treatment was 
performed in 38% of participants in the foam 
group and 31% of participants in the laser group.
Primary Outcomes
Table 2 summarizes results for the primary out-
come measures. At 6 months, the AVVQ score in 
the foam group was significantly higher (indicat-
ing a worse disease-specific quality of life) than 
that in the surgery group, but the difference was 
moderate (effect size, −1.74; 95% confidence in-
terval [CI], −2.97 to −0.50; P = 0.006). The improve-
ment in the AVVQ score in the laser group did 
not differ significantly from that in the surgery 
group. There were no significant differences be-
tween the groups in the EQ-5D score or the SF-36 
physical component score. For the post hoc analy-
sis of treatment with laser versus foam, the only 
significant difference was in the SF-36 mental 
component score, which was slightly higher (bet-
ter generic quality of life) in the laser group than 
in the foam group (effect size, 1.54; 95% CI, 0.01 
to 3.06; P = 0.048).
Results of a post hoc sensitivity analysis of the 
primary outcomes, which excluded the data from 
the center where the largest number of partici-
pants had been recruited, were generally similar, 
except that the AVVQ score was significantly 
worse in the foam group than in the laser group 
(P = 0.02), and the SF-36 mental component score 
was worse in the surgery group than in the laser 
group (P = 0.04) (see Table S3 in the Supplemen-
tary Appendix).
Secondary Outcomes
Quality of Life
Table S4 in the Supplementary Appendix shows 
results for secondary quality-of-life outcomes. At 
6 weeks, significant between-group differences 
(P<0.005) included a lower AVVQ score (indicat-
ing a better disease-specific quality of life) in the 
surgery group than in the foam group (effect size, 
−2.3; 95% CI, −3.7 to −0.9) and lower SF-36 scores 
(indicating a worse generic quality of life) in the 
surgery group than in the laser group for the do-
mains of bodily pain (effect size, −2.7; 95% CI, 
−4.4 to −0.9), vitality (effect size, −2.3; 95% CI, 
−3.9 to −0.8), role limitations due to emotional 
health (effect size, −2.4; 95% CI, −4.0 to −0.8), and 
role limitations due to physical health (effect size, 
−3.5; 95% CI, −5.2 to −1.8). These four SF-36 
domain scores did not differ significantly (with 
P<0.005 considered to indicate statistical signifi-
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cance) between groups at 6 months. For the post 
hoc comparisons of laser treatment versus foam 
treatment, only the EQ-5D score was significantly 
lower (indicating a worse generic quality of life) 
in the foam group at 6 weeks (0.044; 95% CI, 
0.014 to 0.074).
Clinical Outcomes
The venous clinical severity score was moderately 
but significantly lower (indicating less residual 
venous disease) in the surgery group than the 
foam group after 6 weeks, but there was no sig-
nificant difference at 6 months (see Table S5 in 
the Supplementary Appendix). There was no sig-
nificant difference in this score between the la-
ser and the surgery groups or between the laser 
and the foam groups at either time.
At both 6 weeks and 6 months, there were 
fewer residual varicose veins, as assessed by both 
participants and nurses, in the surgery group than 
in the foam group, but the differences were small. 
There were fewer residual varicose veins in the 
surgery group than in the laser group at 6 weeks, 
but not at 6 months, as reported by the nurses 
but not the participants. There were no signifi-
cant differences between the laser and the foam 
Figure 1. Assessment for Eligibility, Randomization, and Outcomes.
A total of 13 participants (1.6%) were excluded after randomization because they had veins greater than 15 mm in 
diameter (5 participants), recurrent varicose veins (3 participants), or coexisting conditions or lack of reflux (5 par-
ticipants).
798 Underwent randomization
6592 Patients were assessed for eligibility
2847 Were ineligible
376 Had unknown eligibility status
3369 Were eligible
2571 Declined to participate
292 Were assigned to undergo
foam sclerotherapy
212 Were assigned to undergo
endovenous laser ablation
294 Were assigned to undergo
surgery
286 Were included in trial
6 Were excluded after randomization
289 Were included in trial
5 Were excluded after randomization
210 Were included in trial
2 Were excluded after randomization
6-Wk follow-up
265 (93%) Completed clinical
assessment
247 (86%) Completed questionnaire
12 (4%) Were withdrawn
6-Wk follow-up
251 (87%) Completed clinical
assessment
237 (82%) Completed questionnaire
29 (10%) Were withdrawn
6-Wk follow-up
193 (92%) Completed clinical
assessment
186 (89%) Completed questionnaire
6 (3%) Were withdrawn
6-Mo follow-up
251 (88%) Completed clinical
assessment
238 (83%) Completed questionnaire
16 (6%) Were withdrawn
6-Mo follow-up
236 (82%) Completed clinical
assessment
214 (74%) Completed questionnaire
33 (11%) Were withdrawn
6-Mo follow-up
183 (87%) Completed clinical
assessment
175 (83%) Completed questionnaire
9 (4%) Were withdrawn
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groups at 6 weeks, but there were fewer residual 
veins in the laser group than in the foam group 
at 6 months, as reported by the participants (but 
not the nurses) (see Table S5 in the Supplemen-
tary Appendix).
The frequency of completely successful ablation 
of great saphenous veins was significantly higher 
among participants who were randomly assigned 
to surgery (84.4%) or laser treatment (83.0%) than 
among those assigned to foam treatment (54.6%, 
P<0.001 for both comparisons). There was no sig-
nificant difference in success rates between the 
surgery and the laser groups (Table 3).
Complications
Serious and nonserious adverse events are shown 
in Table 4. There were no significant differences 
between groups in the number of serious ad-
verse events (see Table S6 in the Supplementary 
Appendix for details of serious adverse events). 
The frequency of any procedural complications 
(i.e., complications occurring during treatment) 
was lower in the laser group (1.0%) than in the 
foam group (6.2%) or the surgery group (7.1%) 
(P<0.001 for both comparisons). At 6 weeks and 
6 months, the frequency of overall complications 
(predominantly lumpiness and skin staining) 
was greatest in the foam group; the complica-
tion rate was significantly greater in the foam 
group than in the surgery group or the laser 
group at 6 weeks and was significantly greater 
in the foam group than in the surgery group at 
6 months.
Discussion
In this multicenter trial comparing foam sclero-
therapy or laser treatment with surgery for the 
treatment of primary varicose veins, quality-of-
life measures at 6 months did not differ substan-
tially between groups. However, patients treated 
with foam had moderately worse outcomes on a 
Characteristic
Laser Group 
(N = 210)
Foam Group 
(N = 286)
Surgery Group 
(N = 289)
Age — yr 49.7±14.4 49.0±13.3 49.2±13.7
Female sex — no. (%) 120 (57.1) 162 (56.6) 163 (56.4)
Body-mass index† 27.0±4.6 27.1±4.4 27.7±4.7
Unilateral involvement — no. (%) 153 (72.9) 215 (75.2) 196 (67.8)
Previous deep-vein thrombosis — no. (%) 6 (2.9) 4 (1.4) 9 (3.1)
Saphenous-vein involvement
Great saphenous vein — no. (%) 182 (86.7) 232 (81.1) 239 (82.7)
Widest diameter — mm‡ 9.1±3.1 8.4±2.7 8.7±2.8
Reflux above the knee only — no. (%) 151 (96.2) 169 (93.9) 180 (98.4)
Reflux above and below the knee — no. (%)§ 6 (3.8) 11 (6.1) 3 (1.6)
Small saphenous vein — no. (%) 14 (6.7) 21 (7.3) 21 (7.3)
Widest diameter — mm 7.1±1.7 7.6±2.2 7.7±3.3
Deep venous reflux — no. (%)¶ 28 (13.7) 47 (16.8) 25 (8.9)
CEAP classification — no. (%)
C2, varicose veins >3 mm in diameter 113 (54.1) 169 (59.1) 147 (51.2)
C3, edema 28 (13.4) 35 (12.2) 39 (13.6)
C4, skin and subcutaneous changes 56 (26.8) 74 (25.9) 90 (31.4)
C5 or C6, skin changes with healed or active venous ulcer 12 (5.7) 8 (2.8) 11 (3.8)
*  Plus–minus values are means ±SD. CEAP denotes clinical, etiologic, anatomical, and pathophysiological.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  For the comparison between the laser and foam groups, P = 0.008.
§  For the comparison between the foam and surgery groups, P = 0.02.
¶  For the comparison between the foam and surgery groups, P = 0.006.
Table 1. Baseline Characteristics of the Study Participants According to Treatment Group.*
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measure of disease-specific quality of life (AVVQ) 
than did those who underwent surgery. These 
differences were small, and their clinical impor-
tance is uncertain.
The frequency of complications (e.g., lumpi-
ness, skin staining, and numbness) was lower 
after treatment with laser than after treatment 
with either foam or surgery; these differences are 
likely to have affected quality of life. However, 
the use of foam sclerotherapy for residual vari-
cosities in a third of the participants in the laser 
group at 6 weeks may have attenuated early 
quality-of-life benefits associated with this treat-
ment as compared with treatment with foam or 
surgery.31
The baseline scores and overall improvements 
in quality of life that we observed were similar 
to those reported in smaller European random-
ized trials, supporting the generalizability of our 
findings.2,5,6,8-10,12,32 The nature and frequency of 
complications were also similar to those previ-
ously reported in the literature.1-16
The three groups had similar improvements 
in the venous clinical severity score at 6 months. 
However, successful ablation of the great saphe-
nous veins at 6 weeks occurred significantly less 
often after foam treatment (complete ablation, 
55%; partial ablation with a patent segment and 
no reflux, 23%) than after either surgery (com-
plete ablation, 84%; partial ablation, 6%) or laser 
treatment (complete ablation, 83%; partial abla-
tion, 8%). Observed ablation rates, in particular 
for foam sclerotherapy, were lower than the rates 
in some previous studies, which used less strict 
definitions of success,1,6,10,14 but were similar to 
the rates reported in two randomized trials that 
Measure
Laser 
Group 
(N = 210)
Foam 
Group 
(N = 286)
Surgery 
Group 
(N = 289)
Surgery 
vs. Foam†
Surgery 
vs. Laser‡
Laser 
vs. Foam§
score effect size (95% CI)
AVVQ¶
Baseline 17.8±9.1 17.6±9.9 18.2±9.1
6 Mo after treatment 7.9±8.4 9.1±7.9 7.8±7.5 −1.7 (−3.0 to −0.5)‖ −0.6 (−2.2 to 0.9) −1.1 (−2.6 to 0.4)
EQ-5D**
Baseline 0.792±0.168 0.803±0.177 0.784±0.175
6 Mo after treatment 0.903±0.171 0.895±0.174 0.881±0.202 0.005  
(−0.025 to 0.035)
−0.015  
(−0.051 to 0.021)
0.025  
(−0.010 to 0.059)
SF-36 physical component††
Baseline 48.6±7.8 48.9±8.0 48.2±8.6
6 Mo after treatment 52.6±7.3 52.3±8.5 52.4±8.9 1.0 (−0.2 to 2.3) 0.1 (−1.4 to 1.6) 0.7 (−0.8 to 2.1)
SF-36 mental component††
Baseline 51.9±9.0 52.4±8.7 51.2±9.4
6 Mo after treatment 53.5±7.7 52.2±9.1 52.1±8.6 0.2 (−1.1 to 1.6) −1.3 (−2.9 to 0.2) 1.5 (0.0 to 3.1)‡‡
*  Plus–minus values are means ±SD.
†  The comparison includes participants from stratum A (eight hospitals offering all three treatment options) and stratum B (three hospitals 
offering treatment with only foam or surgery).
‡  The comparison includes participants from stratum A only.
§  The post hoc comparison of laser versus foam includes participants from stratum A only.
¶  The Aberdeen Varicose Veins Questionnaire (AVVQ) consists of 12 questions and a leg diagram assessing disease-specific quality of life, 
with scores ranging from 0 (best) to 100 (worst).
‖  P = 0.006.
**  The EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D) consists of five questions, each with three response options, with 
scores ranging from −0.594 (worst) to 1 (best).
††  The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) comprises a physical component summary score and a mental 
component summary score, each consisting of the sum of four individual physical domains, with scores ranging from 0 (worst) to 100 
(best).
‡‡  P = 0.048.
Table 2. Estimates of Treatment Effect on Primary Quality-of-Life Outcomes.*
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used definitions of technical success that were 
similar to ours.12,15 In contrast to the assessment 
of ablation in previous trials, we determined 
whether ablation was complete or partial on the 
basis of duplex ultrasound scans obtained by in-
dependent, accredited vascular technologists rath-
er than by the surgeons who had performed the 
treatment. The disparity between clinical mea-
sures of success and technical success observed 
in this study has also been observed in other 
trials of treatment for varicose veins.18,19
For patients undergoing laser treatment, con-
current treatment of varicosities remains contro-
versial.16 A previous, single-center trial showed 
significant improvements in the AVVQ score at 
6 weeks among patients who underwent phle-
bectomy concomitantly with laser therapy, as com-
pared with those who underwent laser therapy 
alone.33 In our study, participants in the laser 
group received treatment directed to the main 
saphenous vein, without concomitant phlebecto-
mies (except at one center). We found no signifi-
cant differences in the AVVQ score among patients 
undergoing laser treatment versus surgery at 
6 weeks, despite the use of concomitant phlebec-
tomies in the surgery group.
The limitations of our study should be ac-
knowledged. First, it was not feasible for the par-
ticipants or assessors to be kept unaware of the 
assigned treatment. Second, we did not include a 
group of patients assigned to a sham procedure 
and thus cannot assess the effect of treatment 
relative to such a control. Third, eight comparisons 
involved primary outcomes, and a large number 
of comparisons involved secondary outcomes; 
thus, it is likely that some differences may have 
occurred by chance. We considered differences for 
secondary outcome measures to be significant 
only for P values of less than 0.005. Fourth, lon-
ger follow-up is needed to assess the durability 
of effects. Finally, although radiofrequency abla-
tion is also used to treat varicose veins, we did not 
include this method in our trial; other studies 
have suggested that it results in clinical outcomes 
similar to those associated with laser treatment.16
In conclusion, our multicenter trial compar-
ing the clinical effectiveness of endovenous laser 
ablation, foam sclerotherapy, and surgery for the 
treatment of varicose veins showed no clinically 
substantial between-group differences in quality 
of life. Moderate differences in disease-specific 
quality of life favored surgery over treatment 
Variable
Laser 
Group
Foam 
Group
Surgery 
Group
Surgery 
vs. Foam†
Surgery 
 vs. Laser‡
Laser 
vs. Foam§
odds ratio (95% CI)
At 6 wk
No. of patients 153 205 192
Complete success — no. (%) 127 (83.0) 112 (54.6) 162 (84.4)
Partial success without reflux — no. (%) 13 (8.5) 47 (22.9) 12 (6.3)
Partial success with reflux — no. (%) 10 (6.5) 9 (4.4) 9 (4.7)
Failure — no. (%) 3 (2.0) 37 (18.0) 9 (4.7) 5.1 (3.1–8.5)¶ 1.2 (0.6–2.3) 3.1 (1.8–5.4)¶
At 6 mo
No. of patients 141 182 173
Complete success — no. (%) 116 (82.3) 79 (43.4) 135 (78.0)
Partial success without reflux — no. (%) 13 (9.2) 35 (19.2) 4 (2.3)
Partial success with reflux — no. (%) 3 (2.1) 9 (4.9) 20 (11.6)
Failure — no. (%) 9 (6.4) 59 (32.4) 14 (8.1) 4.9 (3.1–7.9)¶ 0.8 (0.4–1.5) 4.8 (2.8–8.5)¶
*  Complete success was defined as complete occlusion at the treated vein, partial success as a patent segment of treated vein with or without 
reflux, and failure as more than one patent segment.
†  The comparison includes participants from strata A and B.
‡  The comparison includes participants from stratum A only.
§  The post hoc comparison of laser versus foam includes participants from stratum A only.
¶  P≤0.01.
Table 3. Estimates of the Success of Ablation of the Great Saphenous Vein According to Treatment Group.*
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with foam, and moderate differences in generic 
quality of life favored laser treatment over foam. 
All treatments had similar clinical efficacy, but 
there were fewer complications after laser treat-
ment, and ablation rates were lower after treat-
ment with foam.
The views expressed in this article are those of the authors 
and do not necessarily reflect the views of the National Institute 
for Health Research, the National Health Service, the Depart-
ment of Health, or the funders that provided institutional sup-
port for this study.
Supported by a grant from the Health Technology Assessment 
Programme of the National Institute for Health Research 
(06/45/02). The Health Services Research Unit is funded by the 
Chief Scientist Office of the Scottish Government Health Direc-
torate.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank Janice Cruden for her secretarial support and data 
management; Gladys McPherson and the programming team at 
the Centre for Healthcare Randomised Trials; Tracey Davidson, 
Lynda Constable, Jackie Ellington, Laura Elliott, and Yvonne Fer-
nie for help with scoring the Aberdeen Varicose Vein Question-
naire; Luke Vale and Laura Ternent, our original economists in 
the group; members of the Project Management Group for their 
ongoing advice and support of the trial; members of the study 
team (Graeme MacLennan, Maria Prior, and Denise Bolsover) 
who contributed to the behavioral recovery component of the 
trial; the independent members of the trial steering committee 
(Alun Davies [chair], Ian Loftus, and Jane Nixon) and the data 
and safety monitoring committee (Gerry Stansby [chair], Win-
ston Banya, and Marcus Flather); and the staff members at re-
cruitment sites (see the Supplementary Appendix) who facilitat-
ed recruitment, treatment, and follow-up of trial participants.
Event Laser Group Foam Group Surgery Group
number/total number (percent)
Serious adverse events overall 7/210 (3.3) 11/286 (3.8) 10/289 (3.5)
Serious adverse events related to treatment 2/210 (1.0) 3/286 (1.0) 4/289 (1.4)
Other complications
Any procedural complication during treatment 2/205 (1.0) 17/275 (6.2)† 19/267 (7.1)†
Any complication at 6 wk 103/193 (53.4) 219/265 (82.6)† 168/251 (66.9)‡
Any complication at 6 mo 89/183 (48.6) 144/251 (57.4)§ 109/236 (46.2)
Numbness at 6 wk 22/193 (11.4)¶ 15/265 (5.7) 45/251 (17.9)‖
Numbness at 6 mo 17/183 (9.2)¶ 10/251 (4.0) 37/236 (15.6)‖
Persistent bruising at 6 wk 10/193 (5.2) 49/265 (18.5)† 32/251 (12.7)‡
Persistent bruising at 6 mo 25/183 (13.6) 38/251 (15.2) 40/236 (17.0)
Persistent tenderness and discomfort at 6 wk 41/193 (21.2) 122/265 (46.0)† 79/251 (31.5)†¶
Skin loss or ulceration at 6 wk 0/193 2/265 (0.8) 1/251 (0.4)
Skin loss or ulceration at 6 mo 1/183 (0.6) 2/251 (0.8) 0/236
Lumpiness at 6 wk 36/193 (18.7) 171/265 (64.5)†** 83/251 (33.1)‡
Lumpiness at 6 mo 25/183 (13.6)§ 67/251 (26.6)‡** 17/236 (7.2)‡
Development of thread vein at 6 wk 10/193 (5.2) 27/265 (10.2)‡ 21/251 (8.4)
Development of thread vein at 6 mo 24/183 (13.2) 34/251 (13.6) 26/236 (11.0)
Skin staining at 6 wk 18/193 (9.3) 105/265 (39.6)†** 20/251 (8.0)
Skin staining at 6 mo 32/183 (17.4)§ 92/251 (36.6)†** 24/236 (10.2)
*  The comparison between the foam group and the surgery group includes participants from strata A and B; the com-
parison between the surgery group and the laser group includes participants from stratum A only. The post hoc anal-
ysis of the laser group versus the foam group includes participants from stratum A only; 31% of the patients in the 
laser group also underwent foam treatment of varicosities. Thread veins are small clusters of blue or red veins.
†  P<0.001 for the comparison with the laser group.
‡  P<0.05 for the comparison with the laser group.
§  P<0.05 for the comparison with the surgery group.
¶  P<0.05 for the comparison with the foam group.
‖  P<0.001 for the comparison with the foam group.
**  P<0.001 for the comparison with the surgery group.
Table 4. Serious Adverse Events and Other Complications According to Treatment Group.*
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